Little-Known Biotech Cracks Code to Mitigate Cancer…
What Could FDA Approval Mean For This Global Developer of Innovative Cell-Based Technologies and Therapeutics? Avalon GloboCare Corp. (Nasdaq: AVCO)
6 Developing Reasons Why Avalon GloboCare Corp. (Nasdaq: AVCO) Could Generate Unstoppable Growth Throughout 2022
01
Avalon just announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology - which is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer. (12)
02
Avalon GloboCare Corp. (Nasdaq: AVCO) could be one of the most overlooked Biotech stocks in 2022 with shares trading just above the $.52 range as of 7/29/22. (19)
03
Avalon has jointly filed 16 patent applications, and co-invented with key strategic partners, including a world-leading university. (13)
04
The company is headquartered in a hotbed and breeding ground for successful Biotechs, which was responsible for a staggering 70 new FDA drug approvals between 2020 and 2021. (14)
05
Avalon insiders currently own 63% of available shares, which could indicate a strong belief in the company’s outlook. (15)
06
Aggressive M&A activity in the space with CAR-T funding on the rise, big dollars are pouring into the sector. (16)
Avalon GloboCare Corp. (Nasdaq: AVCO) Insider Buys Millions of Shares of Company Stock in July Alone According to 3rd Party Financial Portal TipRanks.com(20)
Potential “Technical Breakout” to the Upside?
This chart could indicate the potential for a 41% vertical move in Avalon GloboCare Corp. (Nasdaq: AVCO) shares as of 7/29/22
(Scroll down below the chart for the technical analysis)
Looking at the chart above and doing a little technical analysis you can see the following moving averages:
Daily average price is: $.54 (as of 7/29/22)
50 day moving average at $.49
200 day moving average at $.72
13-day exponential moving average $.49 (first line of resistance)
But what you don’t see – is what this actually means in dollars and cents.
Meaning, that if shares of (AVCO) trend above its first line of resistance at the $.49 range, which they have recently crossed, then sailed through its 50 day moving average of $.49… then the next line of resistance is all the way at $.72, which, if reached, would represent a 41.18% potential move. (as of 7/29/22)
How is this possible?
You see, shares of Avalon GloboCare Corp. (Nasdaq: AVCO) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”
…And by definition, the “Descending Triangle Breakout Strategy” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (17)
The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (17)
SUBSCRIBE TO OUR NEWSLETTER FOR MUST READ REPORTS & INVESTOR NEWS.
Getting the Right News Before Everyone Else Does, is FREE…
Avalon GloboCare Corp.
It all starts with your body’s T-Cells …
They’re your immune system’s frontline soldiers in the fight against common infections and everyday maladies.
When you’re stuck at home on bedrest, your T-Cells are hard at work getting you back into healthy shape.
Sometimes though, they’re no match for deadly conditions like blood cancer (more specifically leukemia and non-Hodgkins Lymphoma).
That’s where Chimeric Antigen Receptor T-Cell (or “CAR-T”) therapy comes in.4
CAR-T therapy works by extracting your body’s own T-Cells, then genetically modifying them with a receptor that directly attacks specific types of cancers. The cells are then grown and multiplied in the lab before being re-introduced to the body, where they can hunt down cancerous elements in the body’s bloodstream.
That’s why the experts refer to CAR-T therapy as a potential “Living Cure” for some of the world’s deadliest diseases.
Even in its earliest forms as a treatment for blood cancer, this relatively non-invasive treatment leads to lasting remission in no less than 30-40% of patients.
But one company could potentially drive that success rate much higher …
Avalon GloboCare’s Revolutionary Research
Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.
The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.
Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.2
Avalon GloboCare’s
Avalon GloboCare successfully filed for a $50 Million shelf offering (S3) in January of 2019, and was also staked a $20 Million credit facility from Chairman Daniel Lu.
That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.3
Those types of connections are key to Avalon GloboCare’s vertical integration:
- Upstream: Innovation, R&D, IPs - QTY-code engineered novel targets; AVA-Trap ™ - Next-Gen multi-target, RNA-based Flash-CAR ™ - Angiogenic Exosomes; ACTEX ™
- Midstream: Process development, Bio-production, QC/QA - UPMC: Accredited cGMP/cGTP/FACT/aaBB/CLIA/CAP Facility
- Downstream: Clinical Programs - Medical Team: Lu Daopei Hospital network and over 100 affiliated hospitals, the world’s single largest BMT and CAR-T treatment center; - Commercialization: B-to-B model for product development and global marketing (ACTEX ™ecosystem)
This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.
That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.
Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.2 Avalon is currently expanding patient recruitment and indication.
The “QTY Code” Breakthrough Technology
The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy. (12)
The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D. MIT’s Media Lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development. (12)
A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes. (12)
Avalon Files to Protect “IP”
Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.
The new intellectual property covers three core patent families:
Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.
Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.
Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.
Avalon’s HQ Sits in the Hotbed for Successful Biotech Development
Avalon’s headquarters is in Freehold, NJ, and for those who don’t know, New Jersey has one of the hottest breeding grounds for Biotech.
New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today, with 46 of those firms responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ. And some experts believe that despite recent IPO and capital market challenges, the biotech cluster’s ascension will continue. (14)
Scientific advances and an advantageous New Jersey environment have fueled industry growth. (14)
Avalon’s positioning in New Jersey could prove to be a positive catalyst for growth.
Aggressive M&A Activity in the Space
Needless to say, CAR-T funding and investment activity are on the rise.
CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. (16)
In total, financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute another $2 billion. (16)
M&A activity has seemingly been aggressive with deals like:(16)
- Celgene snagged Juno Therapeutics for $9 billion in 2018
- Bristol-Myers Squibb (BMS) acquired Celgene for $74B in 2019.
- Gilead’s acquisition of Kite Pharma for $11.9 billion
- Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.
In aggregate, there has been nearly $100 billion of market capitalization from CAR-T companies within recent years. (16)
Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.(16)
Maybe that’s why Avalon insiders are holding tight?
According market research portal Finviz.com, Avalon insiders own over 63% of the company shares as of 7/29/22: (15)
Little-Known Biotech Cracks Code to Mitigate Cancer…
What Could FDA Approval Mean For This Global Developer of Innovative Cell-Based Technologies and Therapeutics?
Avalon GloboCare Corp. (Nasdaq: AVCO)
6 Developing Reasons Why Avalon GloboCare Corp. (Nasdaq: AVCO) Could Generate Unstoppable Growth Throughout 2022
01
Avalon just announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology - which is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer. (12)
02
Avalon GloboCare Corp. (Nasdaq: AVCO) could be one of the most overlooked Biotech stocks in 2022 with shares trading just above the $.52 range as of 7/29/22.(19)
03
Avalon has jointly filed 16 patent applications, and co-invented with key strategic partners, including a world-leading university. (13)
04
The company is headquartered in a hotbed and breeding ground for successful Biotechs, which was responsible for a staggering 70 new FDA drug approvals between 2020 and 2021. (14)
05
Avalon insiders currently own 63% of available shares, which could indicate a strong belief in the company’s outlook. (15)
06
Aggressive M&A activity in the space with CAR-T funding on the rise, big dollars are pouring into the sector. (16)
Source 1: https://www.globenewswire.com/news-release/2021/12/17/2354510/0/en/Cancer-Drugs-Market-Size-Worth-Around-US-272-Billion-by-2030.html
Source 2: https://www.youtube.com/watch?v=K2ZnjL0lOM8
Source 3: https://www.youtube.com/watch?v=4zDPUHxzajs
Source 4: https://www.lls.org/sites/default/files/National/USA/Pdf/LLS-CAR-T-cell-Therapy-Timeline.pdf
Source 5: http://www.avalon-globocare.com/
Source 6: https://simplywall.st/stocks/us/healthcare/nasdaq-avco/avalon-globocare
Source 7: https://www.marketwatch.com/press-release/year-end-update-for-this-up-coming-nasdaq-at-the-forefront-of-innovations-in-healthcare-featuring-ai-immunotherapies-avalon-globocare-corp-nasdaqavco-is-avco-the-next-bfri-2022-01-10
Source 8: https://bit.ly/3tZGqcI
Source 9: https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html
Source 10:https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html
Source 11: https://www.youtube.com/watch?v=IUlflfiMZT0
Source 12: https://finance.yahoo.com/news/avalon-globocare-announces-study-featuring-130000405.html
Source 13: https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
Source 14:https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/
Source 15: https://finviz.com/quote.ashx?t=AVCO
Source 16: https://bioinformant.com/product/car-t-funding-brief/
Source 17:https://www.tradingsim.com/day-trading/descending-triangle
Source 18: https://stockcharts.com/h-sc/ui?s=AVCO
Source 19: https://www.barchart.com/stocks/quotes/AVCO/price-history/historical
Source 20: https://www.tipranks.com/stocks/avco/insider-trading